TR201903753T4 - Akciğer rahatsızlıkları için terapötik tedavi. - Google Patents

Akciğer rahatsızlıkları için terapötik tedavi. Download PDF

Info

Publication number
TR201903753T4
TR201903753T4 TR2019/03753T TR201903753T TR201903753T4 TR 201903753 T4 TR201903753 T4 TR 201903753T4 TR 2019/03753 T TR2019/03753 T TR 2019/03753T TR 201903753 T TR201903753 T TR 201903753T TR 201903753 T4 TR201903753 T4 TR 201903753T4
Authority
TR
Turkey
Prior art keywords
lung conditions
therapeutic treatment
conditions
citrulline
administering
Prior art date
Application number
TR2019/03753T
Other languages
English (en)
Inventor
L Summar Marshall
E Barr Frederick
D Fike Candice
L Aschner Judy
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of TR201903753T4 publication Critical patent/TR201903753T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bir öznede bronkopulmoner displazi veya oksijen yetmezliği-tetiklemeli pulmoner hipertansiyon gibi akciğer rahatsızlıklarını tedavi etmek için, sitrülin gibi bir azot oksit öncülünün bir etkili miktarının verilmesini içeren yöntemler ve bileşimler.
TR2019/03753T 2008-01-31 2009-02-02 Akciğer rahatsızlıkları için terapötik tedavi. TR201903753T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2515708P 2008-01-31 2008-01-31

Publications (1)

Publication Number Publication Date
TR201903753T4 true TR201903753T4 (tr) 2019-03-21

Family

ID=40952648

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03753T TR201903753T4 (tr) 2008-01-31 2009-02-02 Akciğer rahatsızlıkları için terapötik tedavi.

Country Status (16)

Country Link
US (1) US20090312423A1 (tr)
EP (1) EP2247297B1 (tr)
JP (4) JP2011511006A (tr)
KR (3) KR20100135729A (tr)
CN (2) CN101969974A (tr)
AU (1) AU2009212692B2 (tr)
BR (1) BRPI0906606A2 (tr)
CA (1) CA2714272C (tr)
DK (1) DK2247297T3 (tr)
ES (1) ES2719530T3 (tr)
HU (1) HUE043235T2 (tr)
PL (1) PL2247297T3 (tr)
PT (1) PT2247297T (tr)
RU (1) RU2557048C2 (tr)
TR (1) TR201903753T4 (tr)
WO (1) WO2009099998A2 (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
SG196863A1 (en) * 2008-01-31 2014-02-13 Univ Vanderbilt Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
JP5666161B2 (ja) * 2010-04-05 2015-02-12 森永製菓株式会社 ヘチマ及び一酸化窒素産生物質を含有する飲食物
RU2733738C2 (ru) 2015-06-29 2020-10-06 Вандербилт Юниверсити Внутривенное введение цитруллина во время хирургического вмешательства
US10265286B2 (en) * 2016-12-28 2019-04-23 Vanderbilt University Sequelae of cardiopulmonary bypass-induced pulmonary injury
AR111082A1 (es) * 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes
CN111315283A (zh) * 2017-08-30 2020-06-19 贝尔罗丰脉冲技术有限公司 吸入性一氧化氮用于治疗与肺病相关的肺高压症的用途
CN111714478B (zh) * 2020-07-14 2023-08-04 江南大学 丙酸钠在制备治疗支气管肺发育不良药物中的应用
US12064409B2 (en) * 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
JP2024111715A (ja) * 2023-02-06 2024-08-19 株式会社ユーグレナ 大気汚染による障害の予防用食品組成物及び大気汚染による障害の予防剤

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5573933A (en) * 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4996236A (en) * 1988-06-22 1991-02-26 Takeda Chemical Industries, Ltd. Therapeutic composition for hepatic encephalopathy
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
GB9018698D0 (en) * 1990-08-24 1990-10-10 Lynxvale Ltd Semiconductive copolymers for use in electroluminescent devices
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
AU651650B2 (en) * 1990-12-04 1994-07-28 Board Of Regents, The University Of Texas System Methods and compositions for the suppression of (NEU) mediated transformation
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
DE69133584D1 (de) * 1990-12-05 2007-12-13 Gen Hospital Corp Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma
US5550316A (en) * 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US5550024A (en) * 1991-04-19 1996-08-27 Biotechnology Research & Development Corporation Genetic markers for pig litter size
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5648061A (en) * 1995-05-24 1997-07-15 Thomas Jefferson University In vivo and in vitro model of cutaneous photoaging
US5743823A (en) * 1996-02-02 1998-04-28 Younger; Gilbert W. Methods and systems for improving the operation of transmissions for motor vehicles
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6358536B1 (en) * 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6796966B2 (en) * 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6358636B1 (en) * 1998-11-05 2002-03-19 Hmt Technology Corporation Thin overlayer for magnetic recording disk
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US6182295B1 (en) * 1999-06-14 2001-02-06 Kevin Sciglia Hat
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
WO2003023007A2 (en) * 2001-09-07 2003-03-20 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
EP1841458B9 (en) * 2005-01-06 2012-12-12 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
US20070184554A1 (en) * 2005-12-01 2007-08-09 Nps Allelix Corp. Biomarker of improved intestinal function
SG196863A1 (en) * 2008-01-31 2014-02-13 Univ Vanderbilt Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
UA53320U (ru) * 2010-01-15 2010-10-11 Виктор Дмитриевич Лукьянчук Способ фармакокоррекции интоксикации летучими компонентами эпоксидных смол кофацином (ацетилцистеином)

Also Published As

Publication number Publication date
EP2247297A4 (en) 2011-05-25
KR20180059582A (ko) 2018-06-04
DK2247297T3 (en) 2019-03-11
US20090312423A1 (en) 2009-12-17
JP2017200940A (ja) 2017-11-09
AU2009212692A1 (en) 2009-08-13
ES2719530T3 (es) 2019-07-11
JP2015044846A (ja) 2015-03-12
HUE043235T2 (hu) 2019-08-28
PT2247297T (pt) 2019-04-24
EP2247297B1 (en) 2019-01-09
WO2009099998A3 (en) 2009-12-30
KR20170005155A (ko) 2017-01-11
JP2019112439A (ja) 2019-07-11
RU2557048C2 (ru) 2015-07-20
CA2714272C (en) 2016-06-28
EP2247297A2 (en) 2010-11-10
CN104083352A (zh) 2014-10-08
WO2009099998A2 (en) 2009-08-13
RU2010132581A (ru) 2012-03-10
BRPI0906606A2 (pt) 2015-07-14
PL2247297T3 (pl) 2019-07-31
CA2714272A1 (en) 2009-08-13
AU2009212692B2 (en) 2014-05-01
KR20100135729A (ko) 2010-12-27
CN101969974A (zh) 2011-02-09
JP2011511006A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
TR201903753T4 (tr) Akciğer rahatsızlıkları için terapötik tedavi.
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
PH12020500197A1 (en) Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
EA201171215A1 (ru) Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EA201391286A1 (ru) Лечение солидных опухолей
DE602005020639D1 (de) Zusammensetzung aus milchsäure und lactoferrin
MY157782A (en) Compositions and methods for the treatment of xerostomia
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
EP2328550A4 (en) MUCOADHERENT COMPOSITIONS AND THEIR USE
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
WO2010123527A3 (en) Use of epidermal growth factor inhibitors in the treatment of viral infection
BR112013029672A2 (pt) uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
FR2956323B1 (fr) Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome